Caribou Biosciences (CRBU) vs Eloxx Pharmaceuticals (ELOX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $51.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | ELOX |
|---|---|---|
| Share price | $0.4812 | $15.18 |
| Market cap | $51.59M | $61.27M |
| 1-day change | -22.06% | +2.02% |
| YTD return | -69.74% | — |
| 1-year return | -82.04% | — |
| 5-year return | -97.69% | — |
| P/E ratio (TTM) | — | 4.40 |
| EPS (TTM) | $-1.08 | $3.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $23.40 |
| 52-week low | $0.45 | $8.20 |
| Distance from 52-week high | -86.39% | -35.13% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1094.93% | +151.98% |
| Average volume | 2.14M | 46.44K |
| Shares outstanding | 107.21M | 4.04M |
| Employees | 97 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Healthcare · Biotechnology · 97 employees
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Healthcare · Biotechnology · 10 employees
CRBU vs ELOX FAQ
Which is bigger, Caribou Biosciences or Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $51.59M for Caribou Biosciences (CRBU).
Are Caribou Biosciences and Eloxx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.